Considering that YY2 is downregulated in clinical HCC lesions as well as in other cancers,[23, 35, 36] and that YY2 downregulation correlates with disease progression and poor prognosis in liver cancer patients, these results suggest a novel YY2‐dependent regulatory mechanism acting on CSCs, along with new therapeutic opportunities for pharmacological targeting CSCs asymmetric division. This evidence concerns the gene YY2 and hepatocellular carcinoma.